Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma
Retinoids are known to control many important biological processes, including differentiation, morphogenesis, growth and tissue homeostasis. More recently, clinical and pre-clinical results provide evidence for an antiproliferative effect of 13-cis-retinoic acid (13cRA) in interferon-alpha (IFN-alph...
Gespeichert in:
| Veröffentlicht in: | Cancer biotherapy & radiopharmaceuticals 1997-01, Vol.12 (3), p.143-147 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 147 |
|---|---|
| container_issue | 3 |
| container_start_page | 143 |
| container_title | Cancer biotherapy & radiopharmaceuticals |
| container_volume | 12 |
| creator | BUER, J PROBST, M DUENSING, S KÖDITZ, H FRANZKE, A DALLMANN, I GANSER, A ATZPODIEN, J |
| description | Retinoids are known to control many important biological processes, including differentiation, morphogenesis, growth and tissue homeostasis. More recently, clinical and pre-clinical results provide evidence for an antiproliferative effect of 13-cis-retinoic acid (13cRA) in interferon-alpha (IFN-alpha) treated renal cell carcinoma patients. The manner in which 13cRA augments antitumor effects and modulates biologic and clinical responses of renal cell carcinoma to IFN-alpha remains elusive. In the present study, we report induction of apoptosis and objective tumor regression in response to 13cRA in advanced renal cell carcinoma patients refractory to IFN-alpha. Among 21 patients treated there were one complete and four partial remissions (objective response rate, 24%; median response duration 8+ months). Preliminary evidence suggests that 13cRA acid may reverse IFN-alpha resistance in renal cell carcinoma. |
| doi_str_mv | 10.1089/cbr.1997.12.143 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78722770</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78722770</sourcerecordid><originalsourceid>FETCH-LOGICAL-c322t-c32f4d4d0ea4380e04621b40ffe62ad250ca28e77feeb7027b700abbc26be82a3</originalsourceid><addsrcrecordid>eNpNkE1LxDAQhoMorq6evUkP4q3dSfqR9CiLX7DgRc9hmk4x0qZr0hX896buIl7eDOR5h-Fh7IpDxkHVK9P4jNe1zLjIeJEfsTNeljJVqhTHcQZVpLVU5YKdh_ABABVU8pQt4kfJiwrOmF331lmDfYKuTaxLvuzkx8RT2I4uUDKNCc9TY0PqabJutCZBY39J6ybyHfnRpdhv33Eu2TChm-Lk4kZDfQz0JvYGvGAnHfaBLg_vkr093L-un9LNy-Pz-m6TmlyIac6uaIsWCItcAUFRCd4U0HVUCWxFCQaFIik7okaCkDEAm8aIqiElMF-y2_3erR8_dxQmPdgwn4KOxl3QUkkhpIQIrvag8WMInjq99XZA_6056Nmujnb1bFdzoaPd2Lg-rN41A7X_-L3OCNwcAAzRaefRRXV_nFAVl1DnP6Ssg9I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78722770</pqid></control><display><type>article</type><title>Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><creator>BUER, J ; PROBST, M ; DUENSING, S ; KÖDITZ, H ; FRANZKE, A ; DALLMANN, I ; GANSER, A ; ATZPODIEN, J</creator><creatorcontrib>BUER, J ; PROBST, M ; DUENSING, S ; KÖDITZ, H ; FRANZKE, A ; DALLMANN, I ; GANSER, A ; ATZPODIEN, J</creatorcontrib><description>Retinoids are known to control many important biological processes, including differentiation, morphogenesis, growth and tissue homeostasis. More recently, clinical and pre-clinical results provide evidence for an antiproliferative effect of 13-cis-retinoic acid (13cRA) in interferon-alpha (IFN-alpha) treated renal cell carcinoma patients. The manner in which 13cRA augments antitumor effects and modulates biologic and clinical responses of renal cell carcinoma to IFN-alpha remains elusive. In the present study, we report induction of apoptosis and objective tumor regression in response to 13cRA in advanced renal cell carcinoma patients refractory to IFN-alpha. Among 21 patients treated there were one complete and four partial remissions (objective response rate, 24%; median response duration 8+ months). Preliminary evidence suggests that 13cRA acid may reverse IFN-alpha resistance in renal cell carcinoma.</description><identifier>ISSN: 1084-9785</identifier><identifier>EISSN: 1557-8852</identifier><identifier>DOI: 10.1089/cbr.1997.12.143</identifier><identifier>PMID: 10851460</identifier><identifier>CODEN: CBRAFJ</identifier><language>eng</language><publisher>Larchmont, NY: Liebert</publisher><subject>Aged ; Antineoplastic agents ; Apoptosis - drug effects ; Biological and medical sciences ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - pathology ; Female ; General aspects ; Humans ; Interferon-alpha - therapeutic use ; Isotretinoin - therapeutic use ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - pathology ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments</subject><ispartof>Cancer biotherapy & radiopharmaceuticals, 1997-01, Vol.12 (3), p.143-147</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c322t-c32f4d4d0ea4380e04621b40ffe62ad250ca28e77feeb7027b700abbc26be82a3</citedby><cites>FETCH-LOGICAL-c322t-c32f4d4d0ea4380e04621b40ffe62ad250ca28e77feeb7027b700abbc26be82a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,3029,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2861709$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10851460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BUER, J</creatorcontrib><creatorcontrib>PROBST, M</creatorcontrib><creatorcontrib>DUENSING, S</creatorcontrib><creatorcontrib>KÖDITZ, H</creatorcontrib><creatorcontrib>FRANZKE, A</creatorcontrib><creatorcontrib>DALLMANN, I</creatorcontrib><creatorcontrib>GANSER, A</creatorcontrib><creatorcontrib>ATZPODIEN, J</creatorcontrib><title>Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma</title><title>Cancer biotherapy & radiopharmaceuticals</title><addtitle>Cancer Biother Radiopharm</addtitle><description>Retinoids are known to control many important biological processes, including differentiation, morphogenesis, growth and tissue homeostasis. More recently, clinical and pre-clinical results provide evidence for an antiproliferative effect of 13-cis-retinoic acid (13cRA) in interferon-alpha (IFN-alpha) treated renal cell carcinoma patients. The manner in which 13cRA augments antitumor effects and modulates biologic and clinical responses of renal cell carcinoma to IFN-alpha remains elusive. In the present study, we report induction of apoptosis and objective tumor regression in response to 13cRA in advanced renal cell carcinoma patients refractory to IFN-alpha. Among 21 patients treated there were one complete and four partial remissions (objective response rate, 24%; median response duration 8+ months). Preliminary evidence suggests that 13cRA acid may reverse IFN-alpha resistance in renal cell carcinoma.</description><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Isotretinoin - therapeutic use</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><issn>1084-9785</issn><issn>1557-8852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkE1LxDAQhoMorq6evUkP4q3dSfqR9CiLX7DgRc9hmk4x0qZr0hX896buIl7eDOR5h-Fh7IpDxkHVK9P4jNe1zLjIeJEfsTNeljJVqhTHcQZVpLVU5YKdh_ABABVU8pQt4kfJiwrOmF331lmDfYKuTaxLvuzkx8RT2I4uUDKNCc9TY0PqabJutCZBY39J6ybyHfnRpdhv33Eu2TChm-Lk4kZDfQz0JvYGvGAnHfaBLg_vkr093L-un9LNy-Pz-m6TmlyIac6uaIsWCItcAUFRCd4U0HVUCWxFCQaFIik7okaCkDEAm8aIqiElMF-y2_3erR8_dxQmPdgwn4KOxl3QUkkhpIQIrvag8WMInjq99XZA_6056Nmujnb1bFdzoaPd2Lg-rN41A7X_-L3OCNwcAAzRaefRRXV_nFAVl1DnP6Ssg9I</recordid><startdate>19970101</startdate><enddate>19970101</enddate><creator>BUER, J</creator><creator>PROBST, M</creator><creator>DUENSING, S</creator><creator>KÖDITZ, H</creator><creator>FRANZKE, A</creator><creator>DALLMANN, I</creator><creator>GANSER, A</creator><creator>ATZPODIEN, J</creator><general>Liebert</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970101</creationdate><title>Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma</title><author>BUER, J ; PROBST, M ; DUENSING, S ; KÖDITZ, H ; FRANZKE, A ; DALLMANN, I ; GANSER, A ; ATZPODIEN, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c322t-c32f4d4d0ea4380e04621b40ffe62ad250ca28e77feeb7027b700abbc26be82a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Isotretinoin - therapeutic use</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BUER, J</creatorcontrib><creatorcontrib>PROBST, M</creatorcontrib><creatorcontrib>DUENSING, S</creatorcontrib><creatorcontrib>KÖDITZ, H</creatorcontrib><creatorcontrib>FRANZKE, A</creatorcontrib><creatorcontrib>DALLMANN, I</creatorcontrib><creatorcontrib>GANSER, A</creatorcontrib><creatorcontrib>ATZPODIEN, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BUER, J</au><au>PROBST, M</au><au>DUENSING, S</au><au>KÖDITZ, H</au><au>FRANZKE, A</au><au>DALLMANN, I</au><au>GANSER, A</au><au>ATZPODIEN, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma</atitle><jtitle>Cancer biotherapy & radiopharmaceuticals</jtitle><addtitle>Cancer Biother Radiopharm</addtitle><date>1997-01-01</date><risdate>1997</risdate><volume>12</volume><issue>3</issue><spage>143</spage><epage>147</epage><pages>143-147</pages><issn>1084-9785</issn><eissn>1557-8852</eissn><coden>CBRAFJ</coden><abstract>Retinoids are known to control many important biological processes, including differentiation, morphogenesis, growth and tissue homeostasis. More recently, clinical and pre-clinical results provide evidence for an antiproliferative effect of 13-cis-retinoic acid (13cRA) in interferon-alpha (IFN-alpha) treated renal cell carcinoma patients. The manner in which 13cRA augments antitumor effects and modulates biologic and clinical responses of renal cell carcinoma to IFN-alpha remains elusive. In the present study, we report induction of apoptosis and objective tumor regression in response to 13cRA in advanced renal cell carcinoma patients refractory to IFN-alpha. Among 21 patients treated there were one complete and four partial remissions (objective response rate, 24%; median response duration 8+ months). Preliminary evidence suggests that 13cRA acid may reverse IFN-alpha resistance in renal cell carcinoma.</abstract><cop>Larchmont, NY</cop><pub>Liebert</pub><pmid>10851460</pmid><doi>10.1089/cbr.1997.12.143</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1084-9785 |
| ispartof | Cancer biotherapy & radiopharmaceuticals, 1997-01, Vol.12 (3), p.143-147 |
| issn | 1084-9785 1557-8852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78722770 |
| source | Mary Ann Liebert Online Subscription; MEDLINE |
| subjects | Aged Antineoplastic agents Apoptosis - drug effects Biological and medical sciences Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Female General aspects Humans Interferon-alpha - therapeutic use Isotretinoin - therapeutic use Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Male Medical sciences Middle Aged Pharmacology. Drug treatments |
| title | Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T06%3A06%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20in%20vitro%20response%20to%2013-cis-retinoic%20acid%20in%20interferon-alpha%20resistant%20renal%20cell%20carcinoma&rft.jtitle=Cancer%20biotherapy%20&%20radiopharmaceuticals&rft.au=BUER,%20J&rft.date=1997-01-01&rft.volume=12&rft.issue=3&rft.spage=143&rft.epage=147&rft.pages=143-147&rft.issn=1084-9785&rft.eissn=1557-8852&rft.coden=CBRAFJ&rft_id=info:doi/10.1089/cbr.1997.12.143&rft_dat=%3Cproquest_cross%3E78722770%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78722770&rft_id=info:pmid/10851460&rfr_iscdi=true |